Jick H.Adverse drug reactions: the magnitude of the problem. J Allergy Clin Immunol. 1984;74:555-557.
2.
Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1999;83:665-700.
3.
Bigby M., Jick S., Jick H., Arndt K.Drug induced cutaneuos reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256:3358-3363.
4.
Roujeau JC, Stern RSSevere adverse cutaneous reactions to drugs. N Engl J Med . 1994;331:1272-1285.
5.
Tas S., Simonart T.Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology. 2003;206:353-356.
6.
Sullivan JR, Shear NHThe drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol. 2001;137:357-364.
7.
Wolkenstein P., Revuz J.Drug-induced severe skin reactions. Incidence, management and prevention. Drug Saf.1995;13:56-68.
Rekhtman D., Eisentein EMGlucocorticoids for treatment of severe pediatric drug hypersensitivity syndrome . Pediatr Asthma Allergy Immunol. 2005;18:156-159.
10.
Ichiche M., Kiesch N., De Bels D.DRESS syndrome associated with HHV-6 reactivation. Eur J Intern Med. 2003;14:498-500.
11.
Descamps V. , Valance A., Edlinger C., et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137:301-304.
12.
Shiohara T. , Inaoka M., Kano Y.Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes viruses and antiviral and anti-drug immune responses. Allergol Int. 2006;55:1-8.
13.
Kano Y., Inaoka M., Shiohara T.Association between anticonvulsant hypersensitivity syndrome and human herpes virus 6 reactivation and hypogammaglobulinemia. Arch Dermatol . 2004;140:183-188.
14.
Inaoka M.Innate immunity and hypersensitivity syndrome. Toxicology . 2005;209:161-163.
15.
Odom RB, James WD, Berger TGAndrews' Diseases of the Skin. 9th ed. Philadelphia, PA: W B Saunders; 2000.
16.
Naisbitt DJ, Britschgi M., Wong G., et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003;63:732-741.
17.
Bachot N., Roujeau JCDifferential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003;4: 561-572.
18.
Gupta A., Eggo MC, Uetrecht JP, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther. 1992;51:56-67.
19.
Eland IA, Dofferhoff AS, Vink R., Zondervan PE, Stricker BHColitis may be part of the antiepileptic drug hypersensitivity syndrome. Epilepsia. 1999;40: 1780-1783.
20.
De Vriese AS , Philippe J., Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature . Medicine (Baltimore). 1995;74:144-151.
21.
Eedy DJ, English JSUpdates from the British Association of Dermatologists 83rd annual meeting, 1-4 July 2003, Brighton, UK. Br J Dermatol.2004; 150:11-32.
22.
Neuman MG, Malkiewicz IM, Shear NHA novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes . Clin Biochem. 2000;33:517-524.
23.
Scheuerman O., Nofech-Moses Y., Rachmel A., Ashkenazi S.Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin. Pediatrics. 2001;107:E14.
